Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators..

Thorax. 2012 Sep;67(9):781-8.

PMID:
22544891
2.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
3.

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.

Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V.

Respir Med. 2012 Jan;106(1):84-90. doi: 10.1016/j.rmed.2011.09.006.

4.

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.

Respir Med. 2013 Feb;107(2):223-32. doi: 10.1016/j.rmed.2012.10.022.

5.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
6.
7.

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators..

Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62. doi: 10.1164/rccm.200910-1500OC.

PMID:
20463178
8.

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; INTENSITY study investigators..

Eur Respir J. 2011 Oct;38(4):797-803. doi: 10.1183/09031936.00191810.

9.

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D; INVIGORATE investigators..

Lancet Respir Med. 2013 Sep;1(7):524-33. doi: 10.1016/S2213-2600(13)70158-9.

PMID:
24461613
10.

Indacaterol therapy in patients with COPD not receiving other maintenance treatment.

Decramer M, Rossi A, Lawrence D, McBryan D.

Respir Med. 2012 Dec;106(12):1706-14. doi: 10.1016/j.rmed.2012.08.022. Review. Erratum in: Respir Med. 2013 Jan;107(1):160. Dosage error in article text.

11.

Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.

Hoshino M, Ohtawa J, Akitsu K.

Pulm Pharmacol Ther. 2015 Feb;30:128-33. doi: 10.1016/j.pupt.2014.08.002.

PMID:
25183687
12.

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.

Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.

Respir Med. 2014 Apr;108(4):584-92. doi: 10.1016/j.rmed.2014.01.006.

13.
14.

Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.

Pulm Pharmacol Ther. 2007;20(6):740-9.

PMID:
17088091
15.

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B; INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy)..

Respir Res. 2010 Oct 5;11:135. doi: 10.1186/1465-9921-11-135.

16.
17.
18.

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.

Farne HA, Cates CJ.

Cochrane Database Syst Rev. 2015 Oct 22;(10):CD008989. doi: 10.1002/14651858.CD008989.pub3. Review.

PMID:
26490945
19.

Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.

Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.

Ther Adv Respir Dis. 2011 Oct;5(5):345-57. doi: 10.1177/1753465811410100. Review.

PMID:
21719531
20.

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

Mahler DA, Buhl R, Lawrence D, McBryan D.

Pulm Pharmacol Ther. 2013 Jun;26(3):348-55. doi: 10.1016/j.pupt.2013.02.006.

PMID:
23434446
Items per page

Supplemental Content

Support Center